Read more about our accomplishments.
Novartis and Avidity have announced that their boards of directors have reached agreement on the acquisition of Avidity for $72 per share, a total transaction value of approximately $12 billion. The premium is approximately 46% above the closing price and…
Lees meer →Johnson & Johnson acquires Intra-Cellular Therapeutics, a company from our portfolio focused on innovative treatments for neurological disorders. The acquisition confirms the value of our selection methodology and delivers an attractive return for our investors. Johnson & Johnson (J&J) today…
Lees meer →Roche acquires Poseida Therapeutics at a premium of more than 215%. Poseida, specialized in cell therapy for cancer treatment, was a position in the Aescap Genetics fund. The substantial premium underscores the value of innovative cell and gene therapy companies…
Lees meer →Receive regular updates on our funds, portfolio developments and market insights.
Register →Please contact us for a personal consultation or subscribe to our newsletter.
